Overview

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
Phase:
Phase 3
Details
Lead Sponsor:
GTx